Inventiva's substantial MASH market opportunity hinges on clinical differentiation and adoption among currently untreated patients. Read more on IVA stock here.
Preclinical data showed that balanced PPARα, PPARδ and PPARγ activation by lanifibranor affects complementary pathways across multiple hepatic cell populations involved in fibrosis in MASH pathogenesisPreclinical data and Phase 2b clinical results showed lanifibranor improved liver sinusoidal endothelial cell alterations and was associated with changes in intrahepatic vascular abnormalities across multiple stages of diseaseAnalysis of plasma cell-free DNA (cfDNA) identified coordinated epigeneti
Inventiva (NASDAQ:IVA) presents a high-stakes clinical binary play, anchored by a cash runway that extends only into Q2 2027 against a €69.5 million first-half net loss. With no commercial products generating revenue, its long-term fundamental story hinges entirely on de-risking its lead asset to capture a portion of an estimated $15 billion MASH market by […]
Detailed price information for Inventiva S.A. ADR (IVA-Q) from The Globe and Mail including charting and trades.
Detailed price information for Inventiva S.A. ADR (IVA-Q) from The Globe and Mail including charting and trades.
Detailed price information for Inventiva S.A. ADR (IVA-Q) from The Globe and Mail including charting and trades.
Motley Fool Press Release.
U.S. futures mixed as Vail Resorts fell after a Q4 loss miss despite beating sales estimates; several stocks also declined premarket.
Inventiva (NASDAQ:IVA) said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth quarter of 2026, after the last patient completed the study’s 72-week visit earlier this month. Chie
On Monday, Inventiva (NASDAQ:IVA) discussed quarterly financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and
Companies Reporting Before The Bell • Kandi Technologies Gr (NASDAQ:KNDI) is likely to report earnings for its first quarter. • Inventiva (NASDAQ:IVA) is expected to report quarterly loss at $0.20 per share on revenue
Inventiva (IVA) reported a H1 net loss Monday of 0.25 euros ($0.28) per diluted share, narrowing fro
Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits1 as of June 30, 2026Cash runway guidance remains unchanged from July 30, 20262Topline results of the Phase 3 NATiV3 clinical trial are expected in the fourth quarter of 2026Key highlights from the first half of 2026 and recent Company updatesManagement to host webcast today at 8:00 AM ET to discuss first-half 2026 financial results Daix (France), New York (New York, United States), September 28, 2026 – Inventiva
Companies Reporting Before The Bell • Tamboran Resources (NYSE:TBN) is estimated to report quarterly loss at $0.30 per share on revenue of $3.82 million. Companies Reporting After The Bell • Inventiva (NASDAQ:IVA) is
Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.
Tipranks Press Release.
Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetesPreclinical data further characterize lanifibranor’s balanced pan-PPAR pharmacology and support a differentiated fluid and cardiac profile relative to TZDs and dual PPARα/γ agonists Daix (France), New York (New York, United States), September 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clin
Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohortTopline results of NATiV3 expected in Q4 2026September investor conference participation and timing of H1 2026 financial results update Daix (France), New York (New York, United States), September 2nd, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of
By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company’s operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for […] The post Chris Benecchi Named Inventiva’s New Chief Operating Officer appeared first on ExecEdge.
Daix (France), New York City (New York, United States), August 31, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Chris Benecchi as Chief Operating Officer. A proven biopharmaceutical leader with extensive experience in building organizations, preparing medicin
Inventiva (IVA) said late Monday it appointed Chris Benecchi as chief operating officer. Benecchi
This is the newest page. Registered accounts read further back.